When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ARVN - Arvinas' ARV-110 Phase 1/2 study hints at efficacy although only in a narrow subset of patients
Arvinas Inc.
Arvinas's (ARVN-28.6%) updated data from the dose escalation portion of Phase 1/2 trial of ARV-110 in metastatic castration-resistant prostate cancer (mCRPC) patients showed that the treatment was generally well-tolerated.
More news on: Arvinas, Inc., Healthcare stocks news,